Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

32 questions · 35 findings · 19 reviews · Headline outcomes only

No studies found 3 · 8.6%GRADE not reported 2 · 5.7%Very low 12 · 34.3%Low 8 · 22.9%Moderate 9 · 25.7%High 1 · 2.9%

Prophylactic corticosteroids vs placebo or no corticosteroids

Pulmonary complications (as defined by study authors, including pneumonia, embolism, reduced pulmonary function, prolonged ventilation, and pleural effusion, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass

Prophylactic corticosteroids may leads to lower pulmonary complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).

1 finding from 1 review

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).

1 finding from 1 review

Aspirin vs low molecular weight heparin

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs vitamin K antagonist (VKA)

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Intervention not reported

Pulmonary embolism · Patients hospitalised following acute myocardial infarction

The review found no eligible studies for this question.

1 finding from 1 review

Low molecular weight heparin vs placebo or no prophylaxis

Pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization

Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).

1 finding from 1 review

Intervention not reported

Pulmonary embolism · Treating bleeding trauma patients

The intervention showed no clear difference in pulmonary embolism (moderate certainty).

1 finding from 1 review